NCT02954991 2024-04-22Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerMirati Therapeutics Inc.Phase 2 Terminated161 enrolled 15 charts
NCT02805660 2021-04-06Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCMirati Therapeutics Inc.Phase 1/2 Terminated83 enrolled 26 charts